Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Plans to Launch Anti-Smoking Chantix in India by End of February

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - On the heels of a study showing one million people die yearly in India from smoking-related illness, Pfizer plans to launch its anti-smoking tablet Chantix (varenicline) by the end of the month, Pfizer India told PharmAsia News

You may also be interested in...



Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India

MUMBAI - A smoking epidemic that kills nearly a million people in India every year has led Pfizer to get aggressive on collaborating with private sector healthcare units to open 600 smoking cessation clinics in the next two years

Pfizer Pushes Champix In India Through Private Hospitals And Clinics As Smoking Epidemic Hits India

MUMBAI - A smoking epidemic that kills nearly a million people in India every year has led Pfizer to get aggressive on collaborating with private sector healthcare units to open 600 smoking cessation clinics in the next two years

Pfizer’s Champix Approved In Japan

TOKYO - Pfizer is hoping to launch its smoking cessation aid Champix (varenicline) in Japan in April after receiving manufacturing and marketing approval from the Ministry of Health Labor and Welfare Jan. 25, Pfizer Japan told PharmAsia News

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel